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Introduction
Skeletal myoblast fusion, which results in the formation of multi­
nucleated myofibers, is critical for embryonic muscle develop­
ment, adult muscle regeneration and maintenance, and muscle 
hypertrophy under certain conditions. The molecular mecha­
nisms underlying myoblast fusion represent one of the central 
questions in skeletal muscle biology (Wakelam, 1985; Jansen 
and Pavlath, 2008). Two molecularly separable stages of fusion 
have been identified in mammalian muscle cells (Jansen and 
Pavlath, 2008). After an early stage of differentiation, includ­
ing cell cycle withdrawal, myogenin expression, and contrac­
tile protein expression, mononucleated myoblasts fuse to form   
nascent myofibers/myotubes. Subsequently, growth and matu­
ration of the muscle cells are achieved through a second­stage 
fusion, which occurs between the nascent myofibers/myotubes 
and myoblasts. Although many regulators of these fusion pro­
cesses have been revealed in recent years (Jansen and Pavlath, 
2008), a better understanding of the regulation is still needed.
The Ser/Thr protein kinase mammalian target of rapa­
mycin (mTOR) mediates signaling in response to nutrient avail­
ability, cellular energy sufficiency, mitogenic signals, and various 
types of stress signals. mTOR signaling regulates a wide range 
of biological processes, including cell growth, various types of 
cellular differentiation, and metabolism (Erbay et al., 2005;   
Sarbassov et al., 2005; Wullschleger et al., 2006). mTOR as­
sembles  two  biochemically  and  functionally  distinct  protein 
complexes, mTORC1 (mTOR complex 1) and mTORC2, which 
are sensitive and insensitive to rapamycin, respectively (Sarbassov 
et al., 2005). Rapamycin­sensitive mTORC1 signaling has   
emerged as a key regulator of skeletal muscle differentiation 
and remodeling. Rapamycin inhibits myoblast differentiation 
in vitro (Coolican et al., 1997; Cuenda and Cohen, 1999; Erbay 
and Chen, 2001), insulin­like growth factor (IGF)–induced myo­
tube hypertrophy in vitro (Rommel et al., 2001; Park et al., 2005), 
compensatory myofiber hypertrophy in vivo, and regrowth   
of myofibers after atrophy (Bodine et al., 2001). mTORC1 is 
also involved in the mechanical stimulation of skeletal muscle 
M
ammalian  target  of  rapamycin  (mTOR)  has 
emerged as a key regulator of skeletal muscle 
development  by  governing  distinct  stages  of 
myogenesis, but the molecular pathways downstream of 
mTOR are not fully understood. In this study, we report 
that expression of the muscle-specific micro-RNA (miRNA) 
miR-1 is regulated by mTOR both in differentiating myo-
blasts  and  in  mouse  regenerating  skeletal  muscle.  We 
have found that mTOR controls MyoD-dependent tran-
scription of miR-1 through its upstream enhancer, most 
likely  by  regulating  MyoD  protein  stability.  Moreover, 
a functional pathway downstream of mTOR and miR-1 
is delineated, in which miR-1 suppression of histone de-
acetylase 4 (HDAC4) results in production of follistatin and 
subsequent myocyte fusion. Collective evidence strongly 
suggests that follistatin is the long-sought mTOR-regulated 
fusion factor. In summary, our findings unravel for the first 
time a link between mTOR and miRNA biogenesis and 
identify an mTOR–miR-1–HDAC4–follistatin pathway that 
regulates myocyte fusion during myoblast differentiation 
in vitro and skeletal muscle regeneration in vivo.
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Despite the well­recognized importance of both miRNAs 
and mTOR in myogenesis, a possible connection between the 
two has never been implicated or examined. In this study, we 
present evidence revealing for the first time the regulation of a 
miRNA by mTORC1 signaling. Furthermore, we have identified   
follistatin as the fusion factor regulated by mTORC1 signaling 
through miR­1 and histone deacetylase 4 (HDAC4) in myoblast 
differentiation and muscle regeneration.
Results
mTORC1 regulates miR-1 levels in  
skeletal muscle
To examine a potential link between miRNA and mTORC1 
signaling in skeletal myogenesis, we performed miRNA micro­
array analyses. We compared miRNA expression profiles of 
C2C12 cells at differentiation time 0 and 72 h, the latter with or 
without rapamycin treatment. Among the miRNAs up­regulated 
during differentiation (Fig. S1 and Table S1), miR­1 expression 
was drastically inhibited by rapamycin. Quantitative RT­PCR 
(qRT­PCR)  results  confirmed  that  miR­1  increased  dramati­
cally during C2C12 differentiation (Fig. 1 A), which is consis­
tent with a previous study (Chen et al., 2006), and the increase 
was almost completely blocked by rapamycin treatment. As ex­
pected, rapamycin abolished myotube formation (not depicted) 
and drastically inhibited the expression of myogenic markers, 
including myogenin, myosin heavy chain (MHC), MEF2A, and 
MEF2C (Fig. S2). To directly confirm mTOR’s role in control­
ling miR­1 levels, we knocked down mTOR in C2C12 cells   
ex vivo (Hornberger et al., 2006). The regulation of skeletal 
myocyte differentiation by mTORC1 occurs at two stages via 
distinct mechanisms. mTORC1 controls the initiation of myo­
blast  differentiation  by  regulating  IGF­II  expression  (Erbay   
and Chen, 2001; Erbay et al., 2003), whereas a late­stage myo­
cyte fusion leading to myotube maturation is regulated by 
mTORC1 through a yet to be identified secreted factor (Park 
and Chen, 2005). These regulatory mechanisms are also re­
capitulated by mTOR functions in muscle regeneration in vivo 
(Ge et al., 2009).
Micro­RNAs (miRNAs) are a class of small noncoding 
RNAs that regulate protein expression mainly by targeting the 
3 untranslated region of messenger RNAs (Bartel, 2004, 2009). 
Intensive studies in recent years have revealed miRNA as a 
principal regulatory mechanism of gene expression, governing 
numerous biological processes across the species (Bushati and 
Cohen, 2007; Bartel, 2009). Several miRNAs have been recog­
nized as important modulators in the development of skeletal 
and cardiac muscle (van Rooij et al., 2008). Among them, miR­1   
is a conserved muscle­specific miRNA that is essential for myo­
genesis. In Caenorhabditis elegans, miR­1 regulates synaptic 
functions at the neuromuscular junctions (Simon et al., 2008). 
In Drosophila melanogaster, deletion of miR­1 leads to defects 
in muscle differentiation or maintenance, presumably by re­
moving the inhibition on the Notch ligand Delta (Sokol and   
Ambros, 2005). In mammals, deletion of miR­1­2 in mice causes 
dysregulation of cardiogenesis (Zhao et al., 2005, 2007), and 
inhibiting miR­1 impairs the differentiation of skeletal myoblasts 
(Chen et al., 2006).
Figure  1.  mTOR  controls  miR-1  levels  dur-
ing  myogenesis  both  in  vitro  and  in  vivo.  
(A)  C2C12  cells  were  induced  to  differenti-
ate  in  the  absence  or  presence  of  50  nM 
rapamycin  (Rap).  RNA  was  isolated  at  the 
indicated time points of differentiation (Diff), 
and miR-1 levels were measured by qRT-PCR.   
(B)  C2C12  cells  were  transduced  with  lenti-
viruses  expressing  two  independent  mTOR 
shRNAs  or  scrambled  shRNA,  selected  with 
puromycin,  and  induced  to  differentiate.  At 
72 h of differentiation, cells were lysed and 
subjected  to  Western  analysis.  59-kD  S6K1 
has an apparent molecular mass of 70 kD on 
SDS-PAGE. (C) Cells treated as in B were har-
vested at the indicated times of differentiation, 
and miR-1 levels were measured by qRT-PCR. 
In both A and C, relative levels are shown as 
fold increase compared with the level at 0 h. 
(D) TA muscles in mice hind limbs were injured 
by intramuscular injection of BaCl2 followed   
by daily intraperitoneal injection of rapamycin. 
On various days AI, injected muscles were 
isolated and homogenized for RNA isolation 
followed  by  quantitative  PCR  to  determine 
relative miR-1 levels, shown as fold increase 
compared  with  uninjured  muscles.  Data  are 
presented as mean ± SD (n = 3).1159 mTOR regulation of miR-1 and follistatin • Sun et al.
which showed accumulation of miR­1 signals adjacent to both 
centrally and peripherally localized nuclei (Fig. S3, enlarged 
image) and dramatic decrease of signals upon rapamycin ad­
ministration. Collectively, our observations suggest that mTORC1 
controls the levels of miR­1 in skeletal myocytes both in vitro 
and in vivo.
mTORC1 regulates transcription of miR-1 
through an upstream enhancer
miRNAs are transcribed as pri­miRNAs, cleaved by Drosha   
to form pre­miRNAs, followed by another cleavage by Dicer, 
which results in mature miRNAs. A blockage by rapamycin at 
any of those steps would result in a decrease of mature miR­1 
levels. As revealed by Northern blotting (Fig. 2 A), rapamycin 
treatment of differentiating C2C12 cells drastically decreased 
the level of mature miR­1 without inducing pre–miR­1 (73 and 
78 nucleotides), indicating that rapamycin is unlikely to block 
the processing of pre–miR­1 to miR­1. The lack of detectable 
pre–miR­1 by Northern analysis is consistent with rapid pro­
cessing by Dicer observed for most miRNAs. To test whether 
the decrease of mature miR­1 could be attributed to a blockage 
in the processing of pri–miR­1 to pre–miR­1, we measured   
pri–miR­1 levels by qRT­PCR. MiR­1 is encoded at two chro­
mosomal loci, resulting in two distinct primary transcripts. As 
shown in Fig. 2 B, rapamycin inhibited rather than enhanced the 
levels of both forms of pri–miR­1, which excludes the possibil­
ity that suppression of pri–miR­1 processing is responsible for 
using lentivirus­delivered small hairpin RNA (shRNA) with two 
independent target sequences, which inhibited S6K1 phosphory­
lation and suppressed MHC expression (Fig. 1 B). At the same 
time, the miR­1 level during differentiation was suppressed by 
mTOR knockdown (Fig. 1 C).
To validate the dependence of miR­1 levels on mTORC1 
in vivo, we examined miR­1 expression in mouse regenerating 
skeletal muscle. Muscle regeneration was induced upon injury 
elicited by barium chloride (BaCl2) injection into the tibialis 
anterior (TA) muscle (Caldwell et al., 1990; Ge et al., 2009). On 
various days after injury (AI), the TA muscle was isolated, and 
miR­1 levels were measured by qRT­PCR. miR­1 was found to 
increase during regeneration, and the increase was blocked by 
daily rapamycin administration to the mice (Fig. 1 D), accom­
panied by inhibition of regeneration as we reported previously 
(Ge et al., 2009). It should be mentioned that others reported a 
decrease of miR­1 levels in injured muscles (Yuasa et al., 2008; 
Greco et al., 2009), which was not observed by us at any time 
point from day 1 to day 21 AI (Fig. 1 D). It has been proposed 
that the temporary decrease of miR­1 during muscle injury is 
associated with the loss of myofibers and induction of fibrosis 
upon injury, rather than muscle regeneration (Greco et al., 2009). 
Thus, it is possible that miR­1 levels do not decline in our ex­
perimental system, owing to less extensive tissue damage in­
duced by BaCl2 compared with the methods used by others 
(Yuasa et al., 2008; Greco et al., 2009). miR­1 expression in re­
generating muscles was also confirmed by in situ hybridization, 
Figure  2.  miR-1  maturation  is  not  affected 
by rapamycin. C2C12 cells were induced to 
differentiate  in  the  absence  or  presence  of   
50 nM rapamycin (Rap). RNA was isolated 
at the indicated time points of differentiation 
(Diff). (A) Northern blotting was performed to 
examine miR-1 (22 nucleotides) and pre–miR-1 
(73 and 78 nucleotides). Let-7a was blotted as 
a loading control. (B) qRT-PCR was performed 
to  measure  the  relative  levels  of  pri–miR-1-1 
and pri–miR-1-2. Data shown are the represen-
tative results of four independent experiments 
(A) and the mean ± SD of three independent 
experiments (B).JCB • VOLUME 189 • NUMBER 7 • 2010   1160
To further investigate the possibility that mTORC1 signal­
ing might regulate the transcription of miR­1, we considered   
the upstream enhancers for the two miR­1 genes that had been 
found to regulate the expression of miR­1 in cardiac muscle (Zhao   
et al., 2005). We set out to examine luciferase reporters for these 
enhancers in C2C12 cells. As shown in Fig. 3 A, the miR­1­2 
enhancer reporter activity increased during C2C12 differentia­
tion, indicating that the enhancer regulating miR­1 in cardiac 
muscle is also functional in skeletal muscle. Remarkably, rapa­
mycin treatment abolished the increase of the enhancer activity 
(Fig. 3 A, gray bars). A reporter for the miR­1­1 enhancer dis­
played similar up­regulation during differentiation and inhibi­
tion by rapamycin (unpublished data). To ask whether the effect 
of rapamycin on miR­1 enhancer was direct or a consequence of 
rapamycin inhibition of differentiation, we examined the effect 
of inhibiting phosphatidylinositol­3­kinase and p38, two path­
ways required for C2C12 differentiation (Kaliman et al., 1996; 
Cuenda and Cohen, 1999). Strikingly, prolonged (3 d) treatment 
of C2C12 cells with either wortmannin or SB203580, specific 
inhibitors of phosphatidylinositol­3­kinase and p38­MAPK, 
respectively, had no impact on the miR­1 enhancer reporter   
activity (Fig. 3 B), although both drugs drastically inhibited the 
differentiation of C2C12 cells from which reporter assays were 
performed. These observations, together with the fact that not 
all miRNAs regulated during differentiation were sensitive to 
rapamycin (Fig. S1 and Table S1), suggest that mTORC1 sig­
naling may directly regulate miR­1 expression through the up­
stream enhancer.
mTORC1 regulates miR-1 through MyoD
Next, we set out to probe the mechanism underlying mTORC1 
regulation of miR­1 transcription. MyoD is a transcription fac­
tor that is essential and specific for skeletal myogenesis. Fur­
thermore, putative MyoD­binding sites have been found in both 
miR­1­1 and miR­1­2 enhancers (Zhao et al., 2005). Indeed, 
expression of recombinant MyoD in C3H10T1/2 cells, which 
lack endogenous MyoD expression, drastically stimulated the 
expression of miR­1 (Fig. 4 A). The expression of recombinant 
MyoD also markedly activated the miR­1 enhancer reporter in 
the same cells (Fig. 4 B). A reporter with the putative MyoD­
binding site on the enhancer mutated was found to be almost 
completely insensitive to the expression of MyoD (Fig. 4 B), 
suggesting that the effect of MyoD on the enhancer is most 
likely direct, rather than a consequence of MyoD induction of 
differentiation in C3H10T1/2 cells (Davis et al., 1987).
Consistent with a role of mTORC1 in regulating miR­1 
transcription,  rapamycin  significantly  diminished  MyoD­ 
induced miR­1 enhancer activity during 24 h of differentiation 
in C3H10T1/2 cells (Fig. 4 C). Furthermore, we observed that 
a short period (4 h) of rapamycin treatment was as effective as 
24­h treatment in suppressing MyoD­induced miR­1 enhancer 
activity (Fig. 4 D), once again confirming that the regulation   
of miR­1 expression by mTORC1 through MyoD is direct. The 
incomplete rapamycin inhibition of the reporter activity may 
suggest the existence of additional pathways in the regulation   
of MyoD activity, but an equally likely possibility is that over­
expression of MyoD partially overrides regulation by mTORC1, 
the decreased mature miR­1 levels. It is noteworthy that the 
steady­state level of pri­miRNA does not directly reflect the   
actual transcription rate because of potentially rapid processing 
of the transcripts. Nevertheless, the increase of both pri–miR­1 
during differentiation and its sensitivity to rapamycin (Fig. 2 B) are   
consistent with transcriptional regulation of the miR­1 genes. 
Collectively, our observations suggest that rapamycin suppresses 
miR­1 levels by impacting the transcription rather than matura­
tion of miR­1.
Figure 3.  Rapamycin inhibits miR-1 enhancer activity. (A) C2C12 cells were 
transfected with the miR-1-2 enhancer reporter or the corresponding enhanc-
erless reporter, induced to differentiate (Diff) in the absence or presence of   
50 nM rapamycin (Rap), and lysed for luciferase assays at the times indicated.   
(B) Cells were transfected as in A and induced to differentiate for 72 h in 
the presence of 50 nM rapamycin, 100 nM wortmannin (Wort), or 1 µM 
SB203580 (SB) followed by cell lysis and luciferase assays. The enhancerless 
reporter activity was subtracted from the enhancer reporter activity for each 
condition, and the data shown have been normalized with 0 h of activity as 1. 
Data shown are the mean ± SD of three independent experiments.1161 mTOR regulation of miR-1 and follistatin • Sun et al.
reported that HDAC inhibitors induced myocyte fusion through   
the production of follistatin (Iezzi et al., 2004), but the iden­
tity of the HDAC was not known. We hypothesized that miR­1   
might promote skeletal myogenesis by suppressing HDAC4 
and subsequently inducing follistatin expression. To examine 
this hypothesis, we first asked whether HDAC4 could be in­
volved in follistatin production and myogenesis. To this end, 
we knocked down HDAC4 in C2C12 cells with a lentivirus­ 
delivered shRNA (Fig. 5 A). Depletion of HDAC4 led to an 
increase in follistatin mRNA levels (Fig. 5 B) as well as the 
amount of secreted follistatin protein (Fig. 5 C). Meanwhile, 
HDAC4 knockdown enhanced myocyte differentiation (Fig. 5 D) 
with an increase in fusion index, defined as the percentage of 
nuclei in multinucleated cells (Fig. 5 E). These data suggest 
that HDAC4 suppresses follistatin production and is a negative 
regulator of myogenic fusion.
Next,  we  examined  the  requirement  of  miR­1  for  fol­
listatin  expression.  Inhibition  of  miR­1  function  was  achieved 
by a locked nucleic acid (LNA)–containing antisense oligo­
nucleotide approach that had been reported to be effective in 
blocking the actions of the targeted miRNAs (Naguibneva et al.,   
2006a). As shown in Fig. 6 A, anti–miR­1 significantly sup­
pressed the mRNA levels of follistatin, suggesting that miR­1   
is  required  for  the  expression  of  follistatin.  In  addition,  the 
inhibition of follistatin by anti–miR­1 was almost completely 
reversed when cells were treated with the HDAC inhibitor   
trichostatin A (TSA; Fig. 6 A). These data are consistent with   
a cascade in which miR­1 regulates follistatin expression through 
impairing an HDAC. At the same time, a negative effect of 
rendering MyoD somewhat constitutively active and thus par­
tially resistant to rapamycin.
To gain further insight into the mechanism by which 
mTOR may control MyoD activity, we examined the endoge­
nous MyoD protein upon rapamycin treatment. As shown in 
Fig. 4 E, rapamycin treatment induced reduction of MyoD   
protein levels in C2C12 cells. The rapid response to rapamycin 
exposure (4 h) is consistent with a direct effect of rapamycin on 
MyoD levels. In addition, the proteasome inhibitor MG­132 
completely reversed the effect of rapamycin on MyoD, suggest­
ing that the stability of MyoD is regulated in a proteasome­ 
dependent manner. A similar effect of rapamycin was found on 
the level of recombinant MyoD in C3H10T1/2 cells (Fig. 4 F), 
further confirming that the decrease of MyoD protein is post­
translational. Indeed, rapamycin treatment has no effect on the 
mRNA levels of MyoD in C2C12 cells (Fig. S4 A) or of recom­
binant MyoD in C3H10T1/2 cells (Fig. S4 B). Collectively, our 
data suggest that mTORC1 controls MyoD by suppressing its 
proteasome­dependent degradation.
miR-1 regulates skeletal myogenesis 
through HDAC4 and follistatin
To delineate the pathway downstream of mTOR and miR­1 in 
myogenesis, we first considered the targets of miR­1. Several po­
tential targets of miR­1 in skeletal and cardiac muscles have 
been reported (Zhao et al., 2005, 2007; Chen et al., 2006; Yang 
et al., 2007). Specifically, miR­1 was shown to promote the dif­
ferentiation of skeletal myoblast by suppressing the expression 
of HDAC4, a class II HDAC (Chen et al., 2006). It was also 
Figure 4.  mTORC1 regulates miR-1 through 
MyoD. (A) C3H10T1/2 cells were transfected 
with MyoD for 24 h followed by extraction of 
total  RNA  and  qRT-PCR  to  measure  relative   
miR-1 levels. (B) C3H10T1/2 cells were cotrans-
fected with MyoD and the miR-1-2 enhancer 
reporter (miR-1–Luc) or the MyoD site-mutated 
reporter (miR-1*–Luc) and induced to differen-
tiate for 24 h followed by luciferase assays.   
(C) C3H10T1/2 cells were cotransfected with 
the miR-1-2 enhancer reporter and two different 
doses of MyoD and induced to differentiate in 
the absence or presence of 50 nM rapamycin 
(Rap) for 24 h followed by luciferase assays. 
(D) C3H10T1/2 cells were transfected as in C 
but with a single dose of MyoD, induced to dif-
ferentiate for 1 d, and treated with 50 nM rapa-
mycin for 4 h followed by luciferase assays. 
For the data in A–D, relative values are shown, 
with  the  following  samples  as  references:   
(A) lower amount of MyoD transfected (100%), 
(B) miR-1–Luc with MyoD (100%), (C) without 
MyoD and without Rap (1), and (D) with MyoD 
without Rap (100%). (E) At the induction of dif-
ferentiation (Diff; 0 h), confluent C2C12 cells 
were treated with 50 nM rapamycin with or 
without 1 µM MG-132 for 4 h followed by cell 
lysis  and  Western  analysis  for  endogenous 
MyoD. (F) C3H10T1/2 cells were transfected 
with MyoD, grown to confluence, and treated 
with 50 nM rapamycin in differentiation me-
dium for 4 h followed by Western analysis of 
the cell lysates for recombinant MyoD. Tubulin 
is shown as a loading control in E and F. Error 
bars indicate mean ± SD.JCB • VOLUME 189 • NUMBER 7 • 2010   1162
We further probed the specific role of HDAC4 in mediat­
ing miR­1 regulation of follistatin. We found that anti–miR­1 
indeed enhanced the expression of HDAC4 modestly but con­
sistently (Fig. 7 A). Furthermore, knockdown of HDAC4 com­
pletely overrode the negative effect of anti–miR­1 on follistatin 
expression (Fig. 7 B) and, at the same time, restored myocyte 
fusion as indicated by both the fusion index and the percentage 
of large myotubes (Fig. 7 C). Collectively, these observations 
strongly support the existence of a miR­1–HDAC4–follistatin 
cascade in the regulation of myogenesis.
anti–miR­1 was found on C2C12 myogenic differentiation   
(Fig.  6  B),  reflected  by  suppressed  expression  of  myogenin 
and MHC (Fig. 6 C). The percentage of myotubes containing 
five or more nuclei was significantly reduced by anti–miR­1   
(Fig.  6  D),  and  the  overall  fusion  index  was  also  lower  in 
anti–miR­1–expressing cells (Fig. 6 E). More importantly, addi­
tion of recombinant follistatin to the cell medium fully rescued the   
myogenic protein expression (Fig. 6 C), myotube size (Fig. 6 D), 
and fusion index (Fig. 6 E) in the presence of anti–miR­1. Inhibi­
tion of HDAC by TSA had a similar rescue effect (Fig. 6, C–E).
Figure  5.  Knockdown  of  HDAC4  enhances 
follistatin  expression  and  myocyte  fusion. 
C2C12 cells were transduced with lentiviruses 
expressing  shRNA  for  HDAC4  or  a  scram-
bled  sequence  as  negative  control  (Scram).   
(A–E)  After  puromycin  selection,  the  cells 
were  induced  to  differentiate  for  72  h  fol-
lowed by Western analysis of cell lysates (A), 
qRT-PCR assays to determine the relative lev-
els of follistatin mRNA (B), ELISA to measure 
relative levels of secreted follistatin protein (C), 
immunostaining  with  anti-MHC  (green)  and 
DAPI  (blue;  D),  and  measurement  of  fusion   
index (E). Bar, 50 µm. One-sample t tests were 
performed in B and C, and a paired two-tailed   
t test was performed in E. *, P ≤ 0.02. Error 
bars indicate mean ± SD.
Figure  6.  miR-1 is required for myocyte fu-
sion  through  HDAC  and  follistatin.  C2C12 
cells were transfected with LNA anti–miR-1 or 
a scrambled LNA oligo as control and induced 
to differentiate. To inhibit HDAC activity, 25 nM 
TSA was added to the growth medium when 
cell density was 60% and removed the next 
day upon switching to differentiation medium. 
Where  indicated,  0.2  µg/ml  recombinant 
follistatin  was  added  to  the  medium  during 
the last 2 d of differentiation. (A) Relative fol-
listatin mRNA levels after 2 d of differentiation 
were determined by qRT-PCR. (B) C2C12 cells   
after 3 d of differentiation were immunostained 
with  anti-MHC  (green)  and  DAPI  (blue).  Bar, 
100 µm. (C) Myogenic marker expression was 
examined by Western analysis in 3-d differenti-
ated C2C12 cells. (D and E) The percentage 
of myotubes containing five or more nuclei (D) 
and the fusion index (E) were calculated. In E, 
paired two-tailed t tests were performed to com-
pare each data with the control. FS, follistatin. 
*, P < 0.05. Error bars indicate mean ± SD.1163 mTOR regulation of miR-1 and follistatin • Sun et al.
This outcome was not unexpected, as rapamycin would block 
the production of both the fusion factor and IGF­II, the latter re­
quired for the initiation of differentiation (Erbay et al., 2003). 
To bypass the initiation of differentiation, thus allowing exami­
nation of myocyte fusion specifically, we added recombinant 
IGF­II to the differentiation medium, which would fully support 
the initial differentiation and formation of nascent myotubes in 
the presence of rapamycin (Erbay et al., 2003; Park and Chen, 
2005). In the presence of both IGF­II and rapamycin, C2C12 
cells differentiated into myotubes but arrested at a small myo­
tube size with fewer myonuclei than mature myotubes (Fig. 9, 
A and C). Strikingly, the addition of recombinant follistatin in 
this system led to a complete rescue of mature myotube size 
(Fig. 9, A and C), suggesting that follistatin is a strong candi­
date for an mTORC1­regulated second­stage fusion factor.
Previously, we had reported that C2C12 cells stably ex­
pressing a rapamycin­resistant (RR) and kinase­inactive (KI) 
mTOR differentiated in the presence of rapamycin but arrested 
at the nascent myotube stage (Park and Chen, 2005). To confirm 
that follistatin was the missing factor in those cells, we added 
follistatin to the medium of the RR/KI mTOR cells containing 
rapamycin. Remarkably, this resulted in a dramatic increase of 
myotube size, as indicated by the higher percentage of myo­
tubes containing five or more nuclei (Fig. 9, B and D). The ef­
fectiveness of follistatin was comparable with that of conditioned 
medium from fully differentiated C2C12 cells. In addition, in­
hibiting HDAC by TSA had a similar effect (Fig. 9, B and D). 
Collectively, these data strongly suggest that follistatin is a fu­
sion factor regulated by mTORC1.
mTORC1 regulates myocyte fusion  
through follistatin
Now that we have established a regulatory pathway from miR­1 
to follistatin via HDAC4, the immediate question is whether 
mTORC1 controls this pathway, in other words, whether inhibi­
tion of mTORC1 enhances HDAC4 expression and in turn sup­
presses follistatin expression. Indeed, we found that rapamycin 
treatment increased HDAC4 protein levels (Fig. 8 A) and at the 
same time markedly suppressed the mRNA level of follistatin 
(Fig. 8 B). Notably, rapamycin’s inhibitory effect on follistatin 
was only obvious at a later stage during differentiation (days 2 
and 3) when myocyte fusion takes place, supporting the idea 
that follistatin is a myogenic factor that promotes fusion rather 
than the initiation of differentiation. The comparable kinetics of 
miR­1 and follistatin expression (dramatic increase of both at 
48 and 72 h of differentiation; Fig. 1 A and Fig. 8 B) are also 
consistent with miR­1 regulation of follistatin.
Previously, we demonstrated that mTORC1 regulates at 
least two distinct processes of myogenesis and that its regula­
tion of the second­stage myocyte fusion leading to myotube 
maturation or growth is through a yet to be identified secreted 
factor (Park and Chen, 2005). In light of the discovery of a con­
nection between mTORC1 and follistatin through miR­1 and 
HDAC4, we wondered whether follistatin might be the long­
sought second­stage fusion factor under the control of mTOR. 
To this end, we tested whether follistatin could rescue myogenic 
differentiation from rapamycin inhibition. When C2C12 cells 
were induced to differentiate in the presence of rapamycin, fol­
listatin alone failed to rescue differentiation (unpublished data). 
Figure 7.  HDAC4 functions downstream of 
miR-1. (A) C2C12 cells were transfected with 
LNA anti–miR-1 or a scrambled LNA oligo 
as  control  and  induced  to  differentiate  for   
72 h. HDAC4 protein levels in cell lysates 
were  examined  by  Western  blotting  and 
quantified  by  densitometry  using  ImageJ 
(National  Institutes  of  Health).  The  ratio 
of HDAC4 to tubulin was normalized with 
scrambled LNA as 1. A one-sample t test was 
performed. *, P < 0.05. (B and C) C2C12 
cells  were  transduced  with  lentiviruses  ex-
pressing shRNA for HDAC4 or a scrambled 
hairpin sequence, puromycin selected, and 
transfected  with  anti–miR-1  or  scrambled 
LNA followed by induction of differentiation 
for 72 h. The cells were subjected to RNA 
isolation and qRT-PCR to measure follistatin 
mRNA  (B)  or  characterization  of  myotube   
fusion (C) as described in Fig. 6. Error bars 
indicate mean ± SD (n = 3).JCB • VOLUME 189 • NUMBER 7 • 2010   1164
in the presence of rapamycin (Fig. 10, B and C), whereas adeno­
virus expressing GFP did not have any effect (not depicted). 
TSA has been shown to induce the expression of follistatin in 
skeletal muscles in vivo (Minetti et al., 2006). Indeed, similar 
to intramuscular expression of recombinant follistatin, systemic 
administration of TSA fully rescued the growth of regenerat­
ing myofibers from rapamycin inhibition (Fig. 10, B and C).   
Collectively, these observations provide in vivo validation for 
follistatin as an mTORC1­regulated myogenic fusion factor.
Discussion
Our study has revealed for the first time regulation of an miRNA 
by mTOR, a master regulator of cell growth and differentiation. 
We have also identified follistatin as the long­sought myogenic 
fusion factor under the regulation of mTORC1 signaling (Park 
and Chen, 2005). We propose a myogenic pathway (Fig. 10 D) in 
which rapamycin­sensitive mTORC1 controls MyoD­dependent 
transcription of miR­1, which in turn suppresses HDAC4 and 
subsequently up­regulates the production of follistatin, stimu­
lating skeletal myocyte fusion in vitro and in vivo. The linearity 
of this pathway presented in this study would be an oversimpli­
fication of the actual regulatory network, as miR­1 and HDAC4 
would most likely have multiple targets in myogenesis, and 
mTOR certainly regulates other myogenic pathways indepen­
dent of miR­1. Nevertheless, our study identifies a functional 
pathway important for myocyte fusion and muscle growth, pro­
viding a new target for therapeutic intervention in muscle repair 
and regeneration.
mTOR regulation of miRNA
Best known as a regulator of protein synthesis through its effec­
tors S6K1 and 4E­BP1 (Gingras et al., 2001; Hay and Sonenberg, 
2004), the rapamycin­sensitive mTORC1 also regulates RNA 
polymerase I–dependent ribosomal DNA transcription through 
the initiation factors TIF­IA, SL­1, and upstream­binding factor 
(Mayer and Grummt, 2006). Regulation of mRNA expression 
has been implicated for mTORC1 as well, although the mecha­
nisms remain to be deciphered. Our discovery that mTORC1 
regulates biogenesis of miRNA further expands the repertoire 
of this master regulator for mammalian cellular and develop­
mental processes.
There are two distinct chromosomal loci for the miR­1 
gene, miR­1­1 and miR­1­2. An upstream enhancer has been 
found at each locus to mediate the regulation of miR­1 expres­
sion in cardiac muscle, and regulatory sites for serum response 
factor, MyoD and MEF2, have been identified in the enhancers 
(Zhao et al., 2005). Our results have indicated that the miR­1 
enhancer activity is indeed up­regulated during skeletal myo­
cyte differentiation and inhibited by rapamycin, suggesting 
mTORC1 regulation of miR­1 expression through this enhancer. 
We have further shown that MyoD mediates mTOR regulation 
of the miR­1 enhancer activity and that mTORC1 controls the 
protein  stability  of  MyoD.  mTOR  regulation  of  MyoD  and   
miR­1 is most likely direct, based on the following observations:   
(a) the effects of rapamycin on MyoD degradation and miR­1 
enhancer activity were acute and not dependent on myogenic 
Follistatin is regulated by mTORC1 during 
muscle regeneration in vivo
Regeneration of damaged adult skeletal muscles involves satel­
lite cell activation and proliferation followed by myoblast dif­
ferentiation and fusion. Systemic administration of rapamycin 
impairs the regeneration of skeletal muscle induced by BaCl2 
injection in mice, suggesting that mTORC1 plays a key role in 
muscle regeneration (Ge et al., 2009). Significantly, follistatin 
mRNA levels increased by about twofold during regeneration, 
and this increase was abolished by rapamycin administration 
(Fig. 10 A), consistent with mTORC1 regulation of follistatin 
in  vivo. We  further  probed  the  involvement  of  follistatin  in 
mTORC1­regulated  myocyte  fusion  and  myofiber  growth   
in vivo. To study myofiber maturation, which relies on myocyte 
fusion, BaCl2­injected muscles were allowed to regenerate for 
7 d, during which time new fibers were formed but not fully 
matured, before rapamycin was systemically administered. As 
shown in Fig. 10 (B and C), rapamycin administration signifi­
cantly diminished the growth of regenerating myofibers, as indi­
cated by the smaller average cross­section area of the fibers. Most 
important, intramuscular injection of adenovirus­expressing   
recombinant follistatin alleviated the negative effect of rapa­
mycin, resulting in normal growth of the regenerating myofibers 
Figure 8.  Rapamycin leads to increased HDAC4 levels and decreased fol-
listatin levels. (A) C2C12 cells were differentiated for 2 d in the presence 
or absence of 50 nM rapamycin (Rap), and the lysates were analyzed 
by Western blotting. Western blots were quantified using ImageJ, and the 
relative ratio of HDAC4 to tubulin is shown. A one-sample t test was per-
formed. *, P < 0.01. (B) C2C12 cells were induced to differentiate in the 
absence or presence of 50 nM rapamycin, and total RNA was isolated at 
the indicated time points of differentiation (Diff). Relative follistatin mRNA 
levels were measured by qRT-PCR with the 24-h sample without rapamycin 
as 1. Data shown are mean ± SD of three independent experiments.1165 mTOR regulation of miR-1 and follistatin • Sun et al.
miRNA profiling of differentiating C2C12 cells has been 
reported by other groups (Chen et al., 2006; Wong and Tellam, 
2008). Although there is some degree of agreement within the 
results obtained by different groups including ours, our data 
have revealed more myogenically regulated miRNAs than the 
other studies, possibly because of the difference in the miRNA 
chips used, robustness of cell differentiation, and/or methods of 
data analysis (e.g., we used statistical significance rather than 
fold change to set the threshold for data selection). In any event, 
our array results have confirmed the up­regulation during dif­
ferentiation of almost all reported regulators of myogenesis in 
addition to miR­1, including miR­24, ­26a, ­27b, ­133, ­206,   
­181, ­214, and ­499 (Table S1; Naguibneva et al., 2006b; Sun 
et al., 2008; Wong and Tellam, 2008; Crist et al., 2009; Juan   
et al., 2009; van Rooij et al., 2009; Williams et al., 2009). Many 
miRNAs not previously reported to be involved in myogenesis 
are found to be up­ or down­regulated during differentiation 
(Table S1), potentially representing novel regulators of myo­
genic pathways that are worthy of future investigation. Intrigu­
ingly, among 50 miRNAs that were differentially expressed 
during myogenesis (out of 500 total), 24 miRNAs other than 
miR­1  displayed  various  degrees  of  rapamycin  sensitivity   
(Fig. S1 and Table S1). Although some of these miRNAs may 
lie far downstream of mTORC1 in myogenesis, it is conceivable 
that other miRNAs in addition to miR­1 may be directly regulated 
differentiation (Fig. 4, D–F), and (b) although rapamycin abol­
ished miR­1 enhancer activity, other drugs that block differenti­
ation did not have any effect (Fig. 3). In addition to the upstream 
enhancers of miR­1 genes, an intragenic enhancer has been   
reported to activate muscle­specific transcription of the bicis­
tronic primary transcript encoding miR­1­2 and miR­133a­1 
(Liu et al., 2007). Interestingly, we found that a reporter of this 
intragenic enhancer was activated during C2C12 cells differen­
tiation and inhibited by rapamycin (Fig. S5). Because MyoD 
also regulates this enhancer (Liu et al., 2007), it raises the possi­
bility that the mTORC1–MyoD axis controls miR­1 transcription 
at multiple levels.
In contrast to mTOR regulation of ribosomal DNA tran­
scription, which requires S6K1 (Mayer et al., 2004), mTOR 
regulation of miR­1 expression does not seem to involve S6K1, 
as knockdown of S6K1 has no effect on miR­1 expression 
during myogenesis (unpublished data). It is conceivable that 
mTORC1 phosphorylates MyoD and, in turn, stabilizes MyoD. 
We have indeed observed that mTOR phosphorylates MyoD   
in vitro (unpublished data). The reported MyoD phosphoryla­
tion sites, Ser5 and Ser200, do not conform to this model, as 
their phosphorylation correlates with degradation of MyoD 
(Song et al., 1998; Tintignac et al., 2004). The exact mechanism   
by  which  mTORC1  regulates  MyoD  stability  is  currently   
under investigation.
Figure  9.  mTORC1  regulates  myocyte  fu-
sion through follistatin. (A) C2C12 cells were 
differentiated  in  the  absence  or  presence 
of 300 ng/ml IGF-II and 50 nM rapamycin 
(Rap) for 3 d. Where indicated, 0.2 µg/ml 
follistatin (FS) was present during the last 2 d   
of  differentiation.  Differentiated  cells  were   
immunostained  with  anti-MHC  (green)  and 
DAPI (blue). (B) C2C12 cells stably expressing   
RR/KI mTOR were induced to differentiate in 
the presence of 50 nM rapamycin for 3 d. 
0.2 µg/ml follistatin was added to the medium 
for the last 2 d of differentiation. 25 nM TSA 
was added when the cells were 60% conflu-
ent and removed the next day upon induction 
of differentiation. Conditioned medium (CM) 
was  collected  daily  from  parental  C2C12 
cells  that  had  been  induced  to  differentiate   
1 d earlier than the RR/KI mTOR cells and fed 
to the latter with 50 nM rapamycin added. 
The cells were immunostained as in A. Bars, 
100 µm. (C and D) Percentage of myotubes 
containing at least five nuclei was calculated 
from the experiments in A and B, respectively. 
All  data  shown  are  mean  ±  SD  of  at  least 
three independent experiments.JCB • VOLUME 189 • NUMBER 7 • 2010   1166
the myogenic inhibitor myostatin (Lee and McPherron, 2001; 
Amthor et al., 2004). The stimulatory effect of follistatin on 
adult muscle growth has been demonstrated in the mdx mice 
(Minetti et al., 2006; Haidet et al., 2008; Nakatani et al., 2008). 
In vitro, follistatin was shown to mediate TSA­ or nitric oxide/
cyclic GMP–induced myoblast fusion (Iezzi et al., 2004; Pisconti 
et al., 2006). It is likely that follistatin plays a role in both the 
initial myoblast fusion and the second­stage fusion, as we have 
observed that differentiating C2C12 cells exposed to recombi­
nant  follistatin  display  increased  fusion  index  in  addition   
to increased size of myotubes (unpublished data). This well 
corroborates our observation that inhibiting miR­1 results in de­
creased myotube size and fusion index (Fig. 6), supporting the 
notion that miR­1 and follistatin act on the same pathway to 
regulate two stages of myocyte fusion. The new regulatory 
pathway for follistatin (Fig. 10 D) discovered in our study 
should expand the therapeutic potential of this important myo­
genic factor.
Materials and methods
Antibodies and other reagents
The antibodies were obtained from the following sources: anti-tubulin was 
obtained  from  Abcam,  anti-MyoD  (5.8A)  was  obtained  from  Imgenex, 
antibodies against HDAC4, mTOR, phospho–T389-S6K1, MEF2A, and 
MEF2C were obtained from Cell Signaling Technology, and all secondary 
antibodies and DAPI were obtained from Jackson ImmunoResearch Labo-
ratories, Inc. The MF20 anti-sarcomeric MHC and F5D anti-myogenin anti-
bodies were obtained from the Developmental Studies Hybridoma Bank 
developed under the auspices of the National Institute of Child Health and 
Human Development, the National Institutes of Health, and maintained by 
by  mTORC1.  Further  characterization  of  those  candidate   
miRNAs will likely enhance our understanding of the myo­
genic regulatory network.
Follistatin as an mTOR-regulated  
fusion factor
Previously, we reported the existence of a fusion factor under the 
control of mTORC1 signaling in an mTOR kinase­dependent 
manner, which promoted maturation of myotubes arrested at the 
nascent myotube stage by the treatment of rapamycin (Park and 
Chen, 2005). Our current study has revealed follistatin as this 
long­sought fusion factor regulated by mTORC1 through an 
miR­1–mediated pathway. Several other secreted factors have 
been found in the conditioned medium of normally maturing 
myotubes but not of rapamycin­arrested nascent myotubes (un­
published data), including the established second­stage fusion   
factor IL­4 (Horsley et al., 2003) and the NF­kB–induced myo­
genic stimulator IL­6 (Baeza­Raja and Muñoz­Cánoves, 2004). 
However, none of them are able to rescue rapamycin­inhibited   
myotube maturation (unpublished data). The capacity of ex­
ogenous follistatin to fully rescue from rapamycin inhibition 
myotube maturation in vitro (Fig. 9) and muscle regeneration 
in vivo (Fig. 10, B and C), together with the inhibitory effect 
of rapamycin on follistatin expression both in vitro and in vivo 
(Fig. 8 B and Fig. 10 A), makes follistatin the major, if not the 
only, fusion factor regulated by mTORC1.
Follistatin, an activin­binding protein essential for multi­
ple aspects of mouse development (Matzuk et al., 1995), is thought 
to control skeletal muscle development through antagonizing 
Figure 10.  Follistatin is regulated by mTORC1 
during muscle regeneration in vivo. (A) Mouse 
hind limb TA muscles were injected with BaCl2 
followed  by  daily  systemic  administration  of 
rapamycin starting 1 d AI. On various days 
indicated, the injected muscles were isolated 
and total RNA extracted followed by qRT-PCR 
to  measure  levels  of  follistatin  mRNA.  Data 
shown are mean ± SD (n = 3). (B) TA muscles 
were  injected  with  BaCl2  followed  by  daily 
systemic  administration  of  rapamycin  (Rap) 
with or without TSA from day 7 to day 13 AI. 
For some animals, a single dose of adenovirus- 
expressing  follistatin  was  injected  into  the 
injured TA muscle on day 7 AI. A schematic 
diagram is shown to summarize the various 
injections of animals. On days 1, 7, or 14 AI, 
the animals were sacrificed, and the injured 
muscles  were  dissected  and  cryosectioned 
followed by hematoxylin and eosin staining. 
Representative images are shown (n = 7 mice 
for each time point). Bar, 50 µm. (C) Cross- 
section areas of regenerating myofibers shown 
in B were measured. Data shown are mean ± SD   
(n = 7 mice for each data point). One-way 
analysis of variance was performed to analyze 
the  data.  Significant  difference  comparing 
each data point to that of day 14 without treat-
ment; *, P < 0.001. (D) A schematic represen-
tation of the myogenic pathway discovered in 
this study. mTORC1 controls MyoD-dependent 
expression of miR-1 that targets HDAC4 and 
subsequently  up-regulates  the  production  of   
follistatin, which in turn governs myocyte fu-
sion in skeletal myogenesis.1167 mTOR regulation of miR-1 and follistatin • Sun et al.
CT method. The following primers were used: mouse follistatin (forward), 
5-AAAACCTACCGCAACGAATG-3 and (reverse) 5-GGTCTGATCCAC-
CACACAAG-3; and mouse -actin (forward), 5-TTGCTGACAGGATG-
CAGAAG-3 and (reverse) 5-ATCCACATCTGCTGGAAGGT-3. Primers 
for pri–miR-1-1 and pri–miR-1-2 were used as described previously (Liu 
et  al.,  2007).  miRNAs  were  quantified  using  quantitative  PCR–based 
miRNA assay kits (Taqman; Applied Biosystems) following the manu-
facturer’s recommendations, with snoRNA 202 as the internal control 
for normalization.
Northern blotting
Antisense DNA oligonucleotides for mature miR-1 and let-7a were end   
labeled  with  -[
32P]ATP.  The  RNA  Decade  Maker  system  (Applied  Bio-
systems) was similarly radiolabeled as size markers. 20 µg/sample RNA 
was separated on 12% denaturing polyacrylamide gels, transferred to   
nylon membranes (GE Healthcare), and UV cross-linked. Prehybridization 
was performed in ultrasensitive hybridization buffer (ULTRAhyb; Applied 
Biosystems) for 2 h at 42°C followed by hybridization with probe in the 
same buffer (10
6 CPM/ml) overnight at 42°C. The membranes were 
washed with 2× SSC and 0.1% SDS at 42°C followed by exposure to x-ray   
films overnight at 80°C.
Luciferase assays
Cells transfected with various enhancer reporters were treated as described 
in Results and Figs. 3 and 4 and lysed in Passive Lysis buffer (Promega).   
Luciferase assays were performed using the Luciferase Assay Systems kit 
(Promega) following the manufacturer’s protocol.
Immunofluorescence microscopy and quantitative analysis of myocytes
C2C12 cells differentiated in 12-well plates were fixed in 3.7% formalde-
hyde (in PBS), permeabilized in 0.1% Triton X-100, and incubated with 
MF-20 (anti-MHC) antibody in 3% BSA (in PBS) followed by fluorescein 
isothiocyanate-conjugated anti–mouse IgG in 3% BSA (in PBS) with 4 µg/
ml DAPI. The stained cells were examined with a fluorescence microscope 
(DMI 4000B; Leica), and the fluorescent images were captured using a 
camera (RETIGA Exi; QImaging). The images were processed as 24-bit   
images using Photoshop (CS2; Adobe). MHC and DAPI signals were pseudo-
colored green and blue, respectively. The fusion index was calculated as 
the ratio of nuclei number in myocytes with two or more nuclei versus the 
total number of nuclei. Each data point was generated from at least 200 
randomly chosen MHC-positive cells or myotubes.
ELISA for follistatin measurement
Relative  follistatin  protein  levels  in  media  collected  from  differentiating 
C2C12 cells were measured using the human follistatin ELISA kit (26% 
cross reactivity with mouse follistatin; R&D Systems) following the manufac-
turer’s protocols.
Adenovirus production
Adenoviruses  expressing  human  follistatin  (AdexCA-FS288)  or  EGFP   
(AdexCA-GFP) under the CAG promoter were provided by W. Vale (Salk 
Institute, La Jolla, CA; Leal et al., 2002). The viruses were amplified through 
infection of 293 cells and purified by ultracentrifugation with a cesium 
chloride gradient (Luo et al., 2007) followed by dialysis against PBS.
Muscle tissue cryosection and histological analysis
TA muscles were isolated by dissection, frozen in liquid nitrogen–cooled   
2-methylbutane, and embedded in TBS tissue freezing medium (Thermo 
Fisher Scientific). Sections of 10-µm thickness were made with a cryostat 
(Microm HM550; Thermo Fisher Scientific) at 20°C, placed on uncoated 
slides, and stained with hematoxylin and eosin. The stained slides were   
examined with a microscope (DMI 4000B), and the images were captured 
with a Fluotar 20× 0.4 NA dry objective (Leica) using a camera (RETIGA 
Exi). The images were processed as 24-bit colored images using Photo-
shop. The cross-section area of myofibers was measured using Q-capture 
Pro software (version 6.0; QImaging). For each muscle section, all central-
nucleated (regenerating) myofibers >100 µm
2 within a 307,200-µm
2 view 
in the center of injury were analyzed.
In situ hybridization
In situ hybridization of miR-1 was performed on cryosections of TA muscles 
prepared as described in the previous paragraph. miR-1 was detected by 
antisense LNA probes labeled with the Dig-3 end-labeling kit (Roche) as 
previously described (Naguibneva et al., 2006b) with some modifications. 
In brief, muscle cryosections were fixed in paraformaldehyde, deproteinized 
The University of Iowa Department of Biological Sciences. Rapamycin was 
obtained from LC Laboratories. Follistatin (mouse FS288) was obtained 
from R&D Systems. TSA, gelatin, polybrene, puromycin, MG-132, and   
custom-designed LNA oligonucleotides were obtained from Sigma-Aldrich.
Tissue culture
C2C12 and C3H10T1/2 cells were maintained in DME (1 g/liter glu-
cose) with 10% fetal bovine serum. For differentiation, cells were seeded in 
plates coated with 0.2% gelatin. Differentiation was induced by switching 
to DME containing 2% horse serum. Transfection of LNA anti–miR-1 and 
luciferase reporters into C2C12 cells was performed using nucleofector 
(solution V; program B-032; Lonza) following the manufacturer’s recom-
mendations. All other transfections were performed with Trans-IT (Mirus) at 
50–60% cell density.
Microarray analysis
miRNA profiling was performed using LNA miRNA arrays (Exiqon), which 
contained capture probes for all miRNAs annotated in miRBase (version 
9.2; http://www.mirbase.org/). Samples were prepared using miRVana 
miRNA isolation kit (Applied Biosystems) without enrichment for small RNA. 
1 µg total RNA was labeled with Cy3 or Cy5 according to the manufac-
turer’s protocols cohybridized to arrays overnight, washed, and scanned   
(GenePix 4000B; MDS Analytical Technologies). Image analysis and edit-
ing were performed using GenePix Pro (version 6.0). Data were analyzed 
using the bioconductor packages with R software. For each comparison,   
F statistics were calculated with results from four independent experiments. 
False discovery rate–adjusted p-value at 0.05 was used as cutoff for statisti-
cal significance.
Muscle regeneration in mice
All animal experiments in this study followed protocols approved by the 
Animal Care and Use Committee at the University of Illinois at Urbana-
Champaign. 10–12-wk-old male FVB mice were used in all experiments. 
Muscle injury was induced by injection of 50 µl BaCl2 (1.2% wt/vol) into 
the TA muscle of the hind limb. As control, saline was injected into the TA 
muscle of the lateral hind limb. Rapamycin (1 µg/g body weight) and/or 
TSA (0.6 µg/g body weight) in a carrier containing 5% Tween 80, 5% 
PEG-400, and 4% ethanol was administrated once daily through intraperi-
toneal injection. Adenovirus (AdexCA-FS288 or AdexCA-GFP) was deliv-
ered by one-time injection of 10
11 viral particles into the TA muscle.
Plasmids
pCDNA3-Flag-MyoD was created in a modified pCDNA3 vector contain-
ing the Flag epitope followed by NotI and XbaI restriction sites in which 
MyoD cDNA was inserted. pGL3-MH100-TK luciferase reporters contain-
ing miR-1 upstream enhancers were provided by D. Srivastava (University 
of California, San Francisco, San Francisco, CA; Zhao et al., 2005). The 
enhancerless reporter was generated from the miR-1-2 enhancer reporter 
construct by deleting the enhancer at KpnI sites. The 2.5-kb miR-1/133a   
intragenic enhancer, provided by E.N. Olson (University of Texas South-
western Medical Center, Dallas, TX; Liu et al., 2007), was subcloned into 
pGL2-promoter (Promega).
Lentivirus-mediated RNAi
shRNAs in the pLKO.1-puro vector for knocking down mTOR and HDAC4 
were purchased from Sigma-Aldrich (MISSION TRC). For viral packaging, 
pLKO-shRNA, pCMV-dR8.91, and pCMV–VSV-G were cotransfected into   
293T cells using FuGENE 6 at 0.5:0.45:0.05 µg (in 1 ml for a 6-well plate).   
Media containing viruses were collected 48 h after transfection. The clone   
IDs (Sigma-Aldrich) for the shRNA constructs used in this study are the   
following: mTOR#1, NM_020009.1-7569s1c1; mTOR#2, NM_020009.1-
5493s1c1; and HDAC4, NM_207225.1-1619s1c1. C2C12 cells were   
transduced with lentiviruses in growth medium containing 8 µg/ml poly-
brene and selected in 2 µg/ml puromycin for 1 d followed by plating into 
12-well plates for differentiation.
Real-time quantitative PCR for mRNA and miRNA
Total RNA was isolated from cultured cells or muscle tissues using the 
mirVana RNA isolation kit (Applied Biosystems). cDNA was synthesized 
from 2 µg total RNA with reverse transcription (SuperScript II; Invitrogen)   
using oligo (dT) primer (Invitrogen). Quantitative PCR was performed on an 
iCycler system (Bio-Rad Laboratories) using a SYBR green PCR kit (Applied 
Biosystems) in a 96-well reaction plate (MicroAmp; Bio-Rad Laboratories) 
following the manufacturer’s protocols. -Actin was used as a reference to 
obtain the relative fold change for target samples using the comparative JCB • VOLUME 189 • NUMBER 7 • 2010   1168
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